Gosset Adipose Tissue Metabolism Overview
Adipose tissue metabolism encompasses the biochemical and cellular processes governing energy storage, mobilization, and utilization within adipose (fat) tissue. It involves lipogenesis (fatty acid synthesis and triglyceride storage), lipolysis (triglyceride breakdown into free fatty acids and glycerol), and the secretion of adipokines, which influence whole-body energy balance, glucose homeostasis, and metabolic health. Dysregulation of adipose tissue metabolism is a key factor in the development of obesity, type 2 diabetes, and cardiovascular disease. Adipose tissue also contributes to thermogenesis via specialized cells that express uncoupling protein 1 (UCP1).
Mechanism of Action
Varies widely depending on the specific drug. Examples: - Thiazolidinediones: PPARγ agonists, increasing insulin sensitivity in adipose tissue. - Metformin: Primarily reduces hepatic glucose production, but also influences adipose tissue metabolism. - Orlistat: Inhibits pancreatic lipase, reducing dietary fat absorption and indirectly affecting adipose tissue lipid storage. - Beta-adrenergic agonists: Stimulate lipolysis in adipose tissue through activation of beta-adrenergic receptors.
Biological Functions
Disease Associations
Safety Considerations
- Dysregulated adipose tissue metabolism can lead to insulin resistance and type 2 diabetes.
- Excessive lipolysis can lead to elevated free fatty acid levels and lipotoxicity.
- Chronic inflammation in adipose tissue can contribute to systemic inflammation and cardiovascular disease.
- Certain drugs targeting adipose tissue metabolism can have side effects such as weight gain, fluid retention, or liver toxicity.
Interacting Drugs
Associated Biomarkers
| Biomarker |
|---|
| Leptin levels |
| Adiponectin levels |
| Resistin levels |
| Free fatty acid levels |
| Triglyceride levels |
| Insulin levels |
| Glucose levels |
| HbA1c |
| Inflammatory markers (e.g., TNF-α, IL-6) |